Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CDXC advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CDXC's RSI Oscillator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where CDXC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CDXC just turned positive on January 14, 2025. Looking at past instances where CDXC's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on January 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CDXC as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 10-day moving average for CDXC crossed bearishly below the 50-day moving average on December 24, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CDXC entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CDXC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.210) is normal, around the industry mean (14.746). P/E Ratio (297.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). CDXC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.950) is also within normal values, averaging (263.573).
a developer of proprietary-based ingredient technologies
Industry Biotechnology
A.I.dvisor indicates that over the last year, CDXC has been loosely correlated with AKBA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXC jumps, then AKBA could also see price increases.
Ticker / NAME | Correlation To CDXC | 1D Price Change % | ||
---|---|---|---|---|
CDXC | 100% | +5.13% | ||
AKBA - CDXC | 34% Loosely correlated | +7.25% | ||
MDGL - CDXC | 31% Poorly correlated | +7.64% | ||
GBIO - CDXC | 26% Poorly correlated | +0.18% | ||
BDTX - CDXC | 26% Poorly correlated | -0.45% | ||
CRSP - CDXC | 25% Poorly correlated | +0.57% | ||
More |